Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 02/27/25
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/13/25
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?Zacks Investment Research • 02/13/25
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis TreatmentInvestors Business Daily • 02/12/25
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 MonthsGlobeNewsWire • 02/12/25
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025GlobeNewsWire • 02/11/25
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R AntagonistGlobeNewsWire • 02/03/25
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic DermatitisGlobeNewsWire • 12/11/24
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 11/08/24
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)Zacks Investment Research • 11/08/24
Anaptys Announces Participation in November and December Investor ConferencesGlobeNewsWire • 11/05/24
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 11/05/24
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million OfferingInvestors Business Daily • 08/14/24